Reportlinker Adds Prostate Cancer - Brazil, China, India and Russia (BRIC) Drug Forecasts and Treatment Analysis to 2020
NEW YORK, Nov. 22, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Prostate Cancer - Brazil, China, India and Russia (BRIC) Drug Forecasts and Treatment Analysis to 2020
Summary
GlobalData's pharmaceutical report, "Prostate Cancer - Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020" is an essential source of information and analysis on the prostate cancer therapeutics market in the emerging BRIC countries. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the prostate cancer therapeutics market in Brazil, Russia, India and China. It analyzes the treatment usage patterns in the BRIC prostate cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the BRIC prostate cancer therapeutics market, highlighting the opportunity for future players.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The scope of the report includes:
- An overview of prostate cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized prostate cancer therapeutics market revenue, the annual cost of therapy and treatment usage patterns (for hormone therapy and hormone resistant or refractory therapy) for the BRIC countries from 2001 to 2009, forecast for 11 years to 2020.
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals and life cycle management activities.
- Analysis of unmet need in the market and target product profiles including the opportunities for targeted products.
- Technology trends analytic framework to assess strength of pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
- An overview of the most promising drugs, including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
- Analysis of the current and future market competition in the global prostate cancer therapeutics market. Company profiles including a business description, a financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A) analysis, which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the Japanese prostate cancer therapeutics market.
- Understanding the treatment preferences of physicians according to disease state and across treatment flow.
- Assessing market sizing, forecasts and quantified growth opportunities in the BRIC prostate cancer therapeutics market up to 2020.
- Quantifying the patient population in the BRIC countries to better design product pricing and launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products.
- Identifying market entry points based on safety, efficacy and pricing parameters.
- Assessing competitiveness of products in market by understanding the strength and weakness of the current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look of at the disease pipeline and identifying the most promising paradigm shifting products.
- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
1 Prostate Cancer: Executive Summary
1.1 The Prostate Cancer Therapeutics Market was Driven by the Growth in Patient Volume and Annual Cost of Hormone-refractory Prostate Cancer Therapy
1.2 The Current Competition in the BRIC Prostate Cancer Therapeutics Market is Weak as None of the Drugs Completely Addressed the Unmet Needs
1.3 The Prostate Cancer Pipeline is Strong with Many Novel First-in-class Molecules in Late-stage Clinical Development
1.4 High Unmet Needs Exist in the Prostate Cancer Therapeutics Market in terms of Efficacy and Safety
2 Disease Overview
2.1 Overview
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System
2.1.2 Jewett-Whitmore system
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.4.1 Localized or Locally Advanced Prostate Cancer
2.4.2 Metastatic Prostate Cancer
2.5 Diagnosis
2.5.1 Digital Rectal Examination
2.5.1.1 Sensitivity
2.5.2 Prostate Specific Antigen Test
2.5.2.1 Sensitivity
2.5.3 Transrectal Ultrasound
2.5.3.1 Sensitivity
2.5.4 Prostate Biopsy
2.5.4.1 Sensitivity
2.6 Pathology
2.6.1 Grading
2.7 Treatment
2.7.1 Watchful Waiting
2.7.2 Radiation therapy
2.7.2.1 External Radiation Therapy
2.7.2.2 Brachytherapy
2.7.3 Surgery
2.7.4 Hormone therapy
2.7.4.1 Luteinizing Hormone-Releasing Hormone (LHRH) Agonists and Antagonists
2.7.4.2 Androgen Receptor Antagonist
2.7.4.3 Orchiectomy
2.7.5 Chemotherapy Options
2.7.6 Other Treatments Being Studied
2.7.6.1 Cryosurgery or Cryoablation
2.7.6.2 High Intensity Focused Ultrasound (HIFU)
2.8 Treatment Guidelines
3 Market Characterization
3.1 BRIC (Brazil, Russia, India and China)
3.1.1 Market Size
3.1.1.1 Sales Value
3.1.1.2 Annual Cost of Therapy
3.1.1.3 Patient Volume
3.1.1.4 Treatment Usage Patterns
3.1.1.4.1 Diseased Population
3.1.1.4.2 Treatment Seeking Population
3.1.1.4.3 Diagnosis Population
3.1.1.4.4 Prescription Population
3.1.2 Forecasts
3.1.2.1 Sales Value
3.1.2.2 Annual Cost of Therapy
3.1.2.3 Patient Volume
3.1.2.4 Treatment Usage Patterns
3.1.2.4.1 Diseased Population
3.1.2.4.2 Treatment Seeking Population
3.1.2.4.3 Diagnosis Population
3.1.2.4.4 Prescription Population
3.2 Brazil
3.2.1 Market Size
3.2.1.1 Sales Value
3.2.1.2 Annual Cost of Therapy
3.2.1.3 Patient Volume
3.2.1.4 Treatment Usage Patterns
3.2.1.4.1 Diseased Population
3.2.1.4.2 Treatment Seeking Population
3.2.1.4.3 Diagnosis Population
3.2.1.4.4 Prescription Population
3.2.2 Drivers and Restraints
3.2.2.1 Drivers of Prostate Cancer Market in Brazil
3.2.2.2 Restraints of Prostate Cancer Market in Brazil
3.2.3 Impact on the Market
3.2.4 Forecasts
3.2.4.1 Sales Value
3.2.4.2 Annual Cost of Therapy
3.2.4.3 Patient Volume
3.2.4.4 Treatment Usage Patterns
3.2.4.4.1 Diseased Population
3.2.4.4.2 Treatment Seeking Population
3.2.4.4.3 Diagnosis Population
3.2.4.4.4 Prescription Population
3.2.5 Future Impact
3.3 Russia
3.3.1 Market Size
3.3.1.1 Sales Value
3.3.1.2 Annual Cost of Therapy
3.3.1.3 Patient Volume
3.3.1.4 Treatment Usage Patterns
3.3.1.4.1 Diseased Population
3.3.1.4.2 Treatment Seeking Population
3.3.1.4.3 Diagnosis Population
3.3.1.4.4 Prescription Population
3.3.2 Drivers and Restraints
3.3.2.1 Drivers of Prostate Cancer Market in Russia
3.3.2.2 Restraints of Prostate Cancer Market in Russia
3.3.3 Impact on the Market
3.3.4 Forecasts
3.3.4.1 Sales Value
3.3.4.2 Annual Cost of Therapy
3.3.4.3 Patient Volume
3.3.4.4 Treatment Usage Patterns
3.3.4.4.1 Diseased Population
3.3.4.4.2 Treatment Seeking Population
3.3.4.4.3 Diagnosis Population
3.3.4.4.4 Prescription Population
3.3.5 Future Impact
3.4 India
3.4.1 Market Size (2001-2009)
3.4.1.1 Sales Value
3.4.1.2 Annual Cost of Therapy
3.4.1.3 Patient Volume
3.4.1.4 Treatment Usage Patterns
3.4.1.4.1 Diseased Population
3.4.1.4.2 Treatment Seeking Population
3.4.1.4.3 Diagnosis Population
3.4.1.4.4 Prescription Population
3.4.2 Drivers and Restraints
3.4.2.1 Drivers of Prostate Cancer Market in India
3.4.2.2 Restraints of Prostate Cancer Market in India
3.4.3 Impact on the Market
3.4.4 Forecasts (2010-2020)
3.4.4.1 Sales Value
3.4.4.2 Annual Cost of Therapy
3.4.4.3 Patient Volume
3.4.4.4 Treatment Usage Patterns
3.4.4.4.1 Diseased Population
3.4.4.4.2 Treatment Seeking Population
3.4.4.4.3 Diagnosis Population
3.4.4.4.4 Prescription Population
3.4.5 Future Impact
3.5 China
3.5.1 Market Size (2001-2009)
3.5.1.1 Sales Value
3.5.1.2 Annual Cost of Therapy
3.5.1.3 Patient Volume
3.5.1.4 Treatment Usage Patterns
3.5.1.4.1 Diseased Population
3.5.1.4.2 Treatment Seeking Population
3.5.1.4.3 Diagnosis Population
3.5.1.4.4 Prescription Population
3.5.2 Drivers and Restraints
3.5.2.1 Drivers of Prostate Cancer Therapeutics Market in China
3.5.2.2 Restraints of Prostate Cancer Market in China
3.5.3 Impact on the Market
3.5.4 Forecasts (2010-2020)
3.5.4.1 Sales Value
3.5.4.2 Annual Cost of Therapy
3.5.4.3 Patient Volume
3.5.4.4 Treatment Usage Patterns
3.5.4.4.1 Diseased Population
3.5.4.4.2 Treatment Seeking Population
3.5.4.4.3 Diagnosis Population
3.5.4.4.4 Prescription Population
3.5.5 Future Impact
3.6 Key Takeaway
4 Competitor Assessment
4.1 Strategic Competitor Assessment
4.1.1 Overview
4.1.2 Benchmarking
4.1.2.1 Clinical Endpoints Benchmarking
4.1.2.2 Safety Profile
4.1.2.3 Annual Cost of Therapy
4.1.3 Current Competitor Assessment
4.2 Product Profiles
4.2.1 Taxotere (docetaxel)
4.2.1.1 Overview
4.2.1.2 Efficacy
4.2.1.3 Safety
4.2.1.4 Clinical study details
4.2.1.5 Annual Cost of Therapy
4.2.1.6 Regulatory Approvals
4.2.1.7 Life Cycle Management (LCM) Activities
4.2.1.8 Product Positioning
4.2.2 Casodex (Bicalutamide)
4.2.2.1 Overview
4.2.2.2 Efficacy
4.2.2.3 Safety
4.2.2.4 Clinical Study Details
4.2.2.5 Annual Cost of Therapy
4.2.2.6 Regulatory Approvals
4.2.2.7 Life Cycle Management (LCM) Activities
4.2.2.8 Product Positioning
4.2.3 Zoladex (Goserelin)
4.2.3.1 Overview
4.2.3.2 Efficacy
4.2.3.3 Safety
4.2.3.4 Annual Cost of Therapy
4.2.3.5 Regulatory Approvals
4.2.4 Eligard (leuprolide acetate)
4.2.4.1 Overview
4.2.4.2 Efficacy
4.2.4.3 Safety
4.2.4.4 Clinical Study Details
4.2.4.5 Annual Cost of Therapy
4.2.4.6 Regulatory Approvals
4.2.4.7 Life Cycle Management (LCM) Activities
4.2.4.8 Product Positioning
4.2.5 Lupron (Leuprolide acetate)
4.2.5.1 Overview
4.2.5.2 Efficacy
4.2.5.3 Safety
4.2.5.4 Clinical Study Details
4.2.5.5 Annual Cost of Therapy
4.2.5.6 Regulatory Approvals
4.2.5.7 Life Cycle Management (LCM) Activities
4.2.6 Firmagon (degarelix)
4.2.6.1 Overview
4.2.6.2 Efficacy
4.2.6.3 Safety
4.2.6.4 Annual Cost of Therapy
4.2.6.5 Clinical Study Details
4.2.6.6 Regulatory Approvals
4.2.7 Novantrone (Mitoxantrone hydrochloride)
4.2.7.1 Overview
4.2.7.2 Efficacy
4.2.7.3 Safety
4.2.7.4 Annual Cost of Therapy
4.2.7.5 Clinical Study Details
4.2.7.6 Regulatory Approvals
4.2.7.7 Life Cycle Management (LCM) Activities
4.2.7.8 Product Positioning
4.2.8 Emcyt (estramustine)
4.2.8.1 Overview
4.2.8.2 Safety
4.2.9 Trelstar (triptorelin)
4.2.9.1 Overview
4.2.9.2 Efficacy
4.2.9.3 Safety
4.2.9.4 Annual Cost of Therapy
4.2.9.5 Clinical Study Details
4.2.9.6 Regulatory Approvals
4.2.9.7 Life Cycle Management (LCM) Activities
4.2.10 Eulexin
4.2.10.1 Overview
4.2.10.2 Efficacy
4.2.10.3 Safety
4.2.10.4 Annual Cost of Therapy
4.2.10.5 Regulatory Approvals
4.2.11 Delestrogen
4.2.11.1 Overview
4.2.11.2 Safety
4.2.12 Gynodiol
4.2.12.1 Overview
4.2.12.2 Safety
4.2.13 Estrace tablet
4.2.13.1 Overview
4.2.13.2 Safety
4.2.14 Tace
4.2.14.1 Overview
4.2.14.2 Safety
4.2.15 Nilandrone
4.2.15.1 Overview
4.2.15.2 Efficacy
4.2.15.3 Safety
4.2.16 Premarin
4.2.16.1 Overview
4.2.16.2 Safety
5 Pipeline Assessment
5.1 Overview
5.2 Pipeline Analysis by Phase of Development
5.3 Pipeline by Mechanism of Action
5.4 Strategic Pipeline Assessment
5.4.1 Technology Trends Analytical Framework
5.5 Trends in Prostate Cancer Pipeline
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development
5.6 Partners in Research and Development
5.6.1 Licensing Agreements by Phase of Development
5.6.1.1 Protox Therapeutics Enters into Licensing Agreement with Kissei Pharmaceutical
5.6.1.2 GTx Inc. Expands its Licensing Agreement with Ipsen S.A.
5.6.1.3 Adamis Pharmaceuticals Enters into Licensing Agreement with Colby Pharmaceutical
5.6.1.4 Teva Pharmaceutical Enters into Licensing Agreement with Oncogenex Pharmaceuticals
5.6.1.5 Algeta ASA Enters into Licensing Agreement with Bayer Schering Pharma AG
5.6.1.6 Ambrilia Biopharma Inc, Enters into Licensing Agreement with Kotinos Pharmaceuticals, Inc.
5.6.1.7 Immunotope, Inc. Enters into Licensing Agreement with ImmunoVaccine Technologies Inc.
5.6.1.8 GenomIdea, Inc. Enters into Licensing Agreement with TSD Japan, Inc.
5.6.1.9 Medivation Inc. Enters into Licensing Agreement with Astellas Pharma Inc.
5.6.2 Licensing Agreements by Geography
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer
5.6.3.1 Ambrilia Biopharma Inc., Extends License Agreement with ZBx Corporation
5.6.3.2 Sangretech Biomedical Amends Licensing Agreement with Bostwick Laboratories
5.7 Most Promising Drugs' Profiles
5.7.1 Provenge (sipuleucel-T)
5.7.1.1 Overview
5.7.1.2 Efficacy
5.7.1.3 Safety
5.7.1.4 Annual Cost of Therapy
5.7.1.5 Clinical Study Details
5.7.1.6 Regulatory Approvals
5.7.1.7 Life Cycle Management (LCM) Activities
5.7.1.8 Product Positioning
5.7.2 Jevtana (cabazitaxel)
5.7.2.1 Overview
5.7.2.2 Efficacy
5.7.2.3 Safety
5.7.2.4 Clinical Study Details
5.7.2.5 Regulatory Approvals
5.7.2.6 Product Positioning
5.7.3 Aflibercept (VEGF Trap)
5.7.3.1 Overview
5.7.3.2 Efficacy
5.7.3.3 Safety
5.7.3.4 Clinical Study Details
5.7.3.5 Collaboration Agreements
5.7.3.6 Marketing Rights
5.7.3.7 Launch Analysis
5.7.4 Ipilimumab
5.7.4.1 Overview
5.7.4.2 Efficacy
5.7.4.3 Safety
5.7.4.4 Clinical Study Details
5.7.4.5 Collaboration agreements
5.7.4.6 Marketing rights
5.7.4.7 Launch analysis
5.7.5 Abiraterone Acetate (CB7630)
5.7.5.1 Overview
5.7.5.2 Efficacy
5.7.5.3 Safety
5.7.5.4 Clinical study details
5.7.5.5 Collaboration agreements
5.7.5.6 Marketing rights
5.7.5.7 Launch Analysis
5.7.6 Zibotentan (ZD4054)
5.7.6.1 Overview
5.7.6.2 Efficacy
5.7.6.3 Safety
5.7.6.4 Clinical trials
5.7.6.5 Collaboration agreement
5.7.6.6 Marketing rights
5.7.6.7 Launch analysis
5.7.7 Sprycel (dasatinib)
5.7.7.1 Overview
5.7.7.2 Efficacy
5.7.7.3 Safety
5.7.7.4 Clinical trials
5.7.7.5 Marketing rights
5.7.7.6 Launch analysis
5.7.8 MDV3100
5.7.8.1 Efficacy
5.7.8.2 Safety
5.7.8.3 Clinical study details
5.7.8.4 Collaboration agreements
5.7.8.5 Launch analysis
5.8 Prostate Cancer Pipeline – Pre-clinical Phase
5.9 Prostate Cancer Pipeline – Phase I
5.10 Prostate Cancer Pipeline – Phase II
5.11 Prostate Cancer Pipeline – Phase III
5.12 Key Takeaway
6 Unmet Need and Target Product Profile
6.1 Unmet Need
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy
6.2 Opportunity for Target Product
6.3 Target Product Profile
6.3.1 Ideal Characteristics
6.3.2 Target Product Description
6.4 Key Takeaway
7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Market Impact Analysis
7.3 Future Market Scenario
7.4 Company Analysis
7.4.1 Market Leadership
7.4.2 Future Players in the Market
7.5 Key Takeaway
8 Company Profiles
8.1 Sanofi-aventis
8.1.1 Business Description
8.1.2 Financial Overview
8.1.3 SWOT Analysis
8.1.3.1 Strengths
8.1.3.1.1 Global Presence
8.1.3.1.2 Market Leadership in Hormone-refractory Prostate Cancer and Broad Product Portfolio
8.1.3.1.3 Strong Research and Development Activities
8.1.3.1.4 Acquisition
8.1.3.2 Weaknesses
8.1.3.2.1 Declining Operating Margin
8.1.3.2.2 Discontinuation of Late Phase Projects
8.1.3.2.3 Reliance on Third Parties
8.1.3.3 Opportunities
8.1.3.3.1 Product Approvals and Launches for Prostate Cancer
8.1.3.3.2 Strategic Agreements
8.1.3.3.3 Focus on Biologics
8.1.3.3.4 Potential Prostate Cancer Market
8.1.3.4 Threats
8.1.3.4.1 Intense Generic Competition
8.1.3.4.2 Pricing Pressures
8.1.3.4.3 Tightening of the FDA's Regulatory Oversight
8.1.3.4.4 Drug Side Effects
8.1.4 Oncology Focus
8.2 Pfizer Inc.
8.2.1 Business Description
8.2.2 Financial Overview
8.2.3 SWOT Analysis
8.2.3.1 Strengths
8.2.3.1.1 Broad Oncology portfolio
8.2.3.1.2 Market Leadership in Pharmaceuticals
8.2.3.1.3 Strong Research and Development Operations
8.2.3.1.4 Global Presence
8.2.3.1.5 Strategic Agreements
8.2.3.1.6 Restructuring of Pharmaceutical Business
8.2.3.2 Weakness
8.2.3.2.1 Discontinued Projects – Sutent for Prostate Cancer Discontinues
8.2.3.2.2 Litigations
8.2.3.2.3 Low Return on Equity
8.2.3.2.4 Decreasing Pharmaceutical Revenues in the US
8.2.3.3 Opportunities
8.2.3.3.1 Increasing Focus on Oncology
8.2.3.3.2 Partnership with GlaxoSmithKline
8.2.3.3.3 Focus on Biologics
8.2.3.3.4 Product Approvals
8.2.3.3.5 Promising Product Pipeline
8.2.3.4 Threats
8.2.3.4.1 Over Dependence on Lipitor and Other Key Products
8.2.3.4.2 Patent Expirations and Generic Competition
8.2.3.4.3 Tightening of the FDA's Regulatory Oversight
8.2.3.4.4 Global Price Pressures
8.2.3.4.5 Emergence of Biogenerics / Biosimilars
8.2.4 Oncology Focus
8.3 AstraZeneca
8.3.1 Business Description
8.3.2 Financial Overview
8.3.3 SWOT Analysis
8.3.3.1 Strength
8.3.3.1.1 Strong Prostate Cancer Pipeline
8.3.3.1.2 Efficient Use of Resources
8.3.3.1.3 Diversified Product Portfolio
8.3.3.1.4 Global Presence
8.3.3.2 Weaknesses
8.3.3.2.1 Declining Sales
8.3.3.2.2 Litigations
8.3.3.2.3 Patent Infringement
8.3.3.2.4 Declining Market Share in Sector
8.3.3.2.5 Limited Liquidity Position
8.3.3.3 Opportunities
8.3.3.3.1 Market Potential and Growth in the Prevalence of Cancers
8.3.3.3.2 Inclusion of Prostate Cancer Drugs in National Reimbursable Drugs List (NRDL)
8.3.3.3.3 Product Pipeline
8.3.3.3.4 Potential Cardiovascular market
8.3.3.4 Threats
8.3.3.4.1 Patent Expiry of Key Prostate Cancer Products
8.3.3.4.2 Tightening of the FDA's Regulatory Oversight
8.3.3.4.3 Competitive Pressures from Generic Manufacturers
8.3.4 Oncology Focus
8.4 Bristol-Myers Squibb
8.4.1 Business Description
8.4.2 Financial Overview
8.4.3 SWOT Analysis
8.4.3.1 Strengths
8.4.3.1.1 Strong Prostate Cancer Pipeline
8.4.3.1.2 Strong Growth Prospects
8.4.3.1.3 Focused R&D Activities
8.4.3.1.4 Financial Performance
8.4.3.2 Weaknesses
8.4.3.2.1 Challenges in the Development and Commercialization of New Products
8.4.3.2.2 Declining Market Share in Sector
8.4.3.2.3 Legal Proceedings
8.4.3.2.4 Dependence on the US Market
8.4.3.3 Opportunities
8.4.3.3.1 Changing Demographics
8.4.3.3.2 Alliances and Agreements
8.4.3.3.3 Rising Healthcare Expenditure in the US
8.4.3.3.4 Strategic Divestitures and Acquisitions
8.4.3.3.5 Emerging Markets
8.4.3.4 Threats
8.4.3.4.1 Pricing Pressures
8.4.3.4.2 PLAVIX- Data Protection Expiry
8.4.3.4.3 Stringent Government Regulations
8.4.3.4.4 Rise of Generics
8.4.4 Oncology Focus
8.5 Medivation
8.5.1 Business Description
8.5.2 SWOT Analysis
8.5.2.1 Strengths
8.5.2.1.1 Collaboration with Astellas
8.5.2.1.2 Successful Phase I and II Clinical Trials for Prostate Cancer Product
8.5.2.1.3 Focused Research and Development Activities
8.5.2.2 Weaknesses
8.5.2.2.1 Lack of Product Revenues
8.5.2.2.2 History of Losses
8.5.2.2.3 Lack of Manufacturing Facilities
8.5.2.3 Opportunities
8.5.2.3.1 Market Potential – Focus on Major Therapeutic Areas
8.5.2.3.2 Drug Pipeline for Prostate Cancer
8.5.2.4 Threats
8.5.2.4.1 Tightening of the FDA's Regulatory Oversight
8.5.2.4.2 Increased Pricing Control
8.5.2.4.3 Uncertainties in R&D
8.5.2.4.4 Tough Credit Market Conditions
8.5.3 Oncology Focus
8.6 Takeda Pharmaceuticals
8.6.1 Business Description
8.6.2 SWOT Analysis
8.6.2.1 Strengths
8.6.2.1.1 Broad Product Portfolio
8.6.2.2 Weaknesses
8.6.2.2.1 Declining Revenues
8.6.2.3 Opportunities
8.6.2.3.1 Strategic Acquisitions in Prostate Cancer Market
8.6.2.3.2 Focus on Oncology and Positive Outlook for Oncology
8.6.2.4 Threats
8.6.2.4.1 Changing Pharmaceutical Industry
8.6.2.4.2 Probability of Product Failures
8.7 Dendreon Corporation
8.7.1 Business Description
8.7.2 SWOT Analysis
8.7.2.1 Strengths
8.7.2.1.1 Lead Product – Provenge
8.7.2.1.2 Sturdy Research and Development Activities
8.7.2.2 Weakness
8.7.2.2.1 Pending Litigation
8.7.2.2.2 Declining Operating Margin
8.7.2.3 Opportunities
8.7.2.3.1 Growth in the Prevalence of Cancer
8.7.2.3.2 Changing Demographics
8.7.2.3.3 Emerging Markets
8.7.2.4 Threats
8.7.2.4.1 Intense Competition
8.7.2.4.2 Use of Hazardous Materials
8.7.2.4.3 Tightening of the FDA's Regulatory Oversight
8.7.2.4.4 Dependence on Single Source Vendors
8.8 Johnson and Johnson
8.8.1 Business Description
8.8.1.1.1 Pharmaceutical Segment Overview
8.8.2 SWOT Analysis
8.8.2.1 Strengths
8.8.2.1.1 Strong Prostate Cancer Pipeline Product – Abiraterone
8.8.2.1.2 Strong In-house Research Capabilities
8.8.2.1.3 Widespread Geographical Presence
8.8.2.1.4 Diversified Product Offerings
8.8.2.1.5 Strong Liquidity Position
8.8.2.2 Weakness
8.8.2.2.1 Underperforming Pharmaceuticals Segment
8.8.2.2.2 Declining Market Share in the Sector
8.8.2.2.3 Product Recalls
8.8.2.2.4 Patent Expiries
8.8.2.2.5 Illegal Promotion of Topamax
8.8.2.3 Opportunities
8.8.2.3.1 Strategic Acquisitions
8.8.2.3.2 Growth in the Prevalence of Cancer
8.8.2.3.3 Changing Demographics
8.8.2.3.4 New Product Launches and Strong Pipeline
8.8.2.3.5 Global Pharmaceutical Market
8.8.2.4 Threats
8.8.2.4.1 Litigation and Legal Claims
8.8.2.4.2 Regulatory Requirements
8.8.2.4.3 Competitive Pressures
8.8.2.4.4 Increased Pricing Control
8.8.3 Oncology Focus
8.9 Auron Healthcare GmbH
8.9.1 Business Description
8.10 Oncogenex Pharmaceuticals, Inc.
8.10.1 Business Description
8.11 Agennix AG
8.11.1 Business Description
8.12 GTx, Inc.
8.12.1 Business Description
8.13 GlaxoSmithKline plc.
8.13.1 Business Description
8.13.2 Financial Overview
8.13.3 SWOT Analysis
8.13.3.1 Strengths
8.13.3.1.1 Strong Financial Performance
8.13.3.1.2 Diversified Product Portfolio
8.13.3.1.3 Focused Research and Development Capabilities
8.13.3.1.4 Global Manufacturing and Supply Network
8.13.3.2 Weaknesses
8.13.3.2.1 Patent Infringement Claims
8.13.3.2.2 Limited Investor Confidence
8.13.3.3 Opportunities
8.13.3.3.1 New Product Launches and Approval
8.13.3.3.2 Strategic Agreements
8.13.3.3.3 Growth in Emerging Markets
8.13.3.3.4 Market Potential – Oncology
8.13.3.3.5 Target Indications - Market Potential
8.13.3.4 Threats
8.13.3.4.1 Competitive Pressures
8.13.3.4.2 Growing Parallel Trade
8.13.3.4.3 Increase in Prevalence of Counterfeit Drugs
8.13.3.4.4 Uncertain R&D Outcomes
8.13.4 Oncology Focus
9 M&A Analysis
9.1 Key Highlights
9.2 Key Deals' Analysis
9.2.1 Johnson & Johnson Acquires Cougar Biotechnology
9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals
9.2.3 Tolmar Holding Acquires QLT USA from QLT
9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics
9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co.
9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs
9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax
9.2.8 GPC Biotech Merges with Agennix
9.2.9 Eli Lilly Acquires ImClone
9.2.10 BBM Holdings Acquires YM BioSciences
9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals
9.3 M&A Deals by Geography
9.4 M&A Deals by Deal Size
10 Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.3.1 Epidemiology-based Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel validation
10.3.6 Contact Us
10.3.7 Disclaimer
10.3.8 Sources
1.1 List of Tables
Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010
Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010
Table 3: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2001–2009
Table 4: Prostate Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2001–2009
Table 5: Prostate Cancer Therapeutics Market, BRIC, Patient Volume, 2001–2009
Table 6: Prostate Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2001–2009
Table 7: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2009–2020
Table 8: Prostate Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2009–2020
Table 9: Prostate Cancer Therapeutics Market, BRIC, Patient Volume (absolute), 2009–2020
Table 10: Prostate Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2009–2020
Table 11: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001-2009
Table 12: Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001-2009
Table 13: Prostate Cancer Therapeutics Market, Brazil, Patient Volume ('000s), 2001-2009
Table 14: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2001-2009
Table 15: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2009-2020
Table 16: Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2009-2020
Table 17: Prostate Cancer, Brazil, Patient Volume ('000s), 2009-2020
Table 18: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2009-2020
Table 19: Prostate Cancer, Russia, Sales Value ($m), 2001-2009
Table 20: Prostate Cancer, Russia, Annual Cost of Therapy ($), 2001-2009
Table 21: Prostate Cancer, Russia, Patient Volume (Thousands), 2001-2009
Table 22: Prostate Cancer, Russia, Treatment Usage Patterns, 2001-2009
Table 23: Prostate Cancer, Russia, Sales Value ($m), 2009-2020
Table 24: Prostate Cancer, Russia, Annual Cost of Therapy ($), 2009-2020
Table 25: Prostate Cancer, Russia, Patient Volume (Thousands), 2009-2020
Table 26: Prostate Cancer, Russia, Treatment Usage Patterns, 2009-2020
Table 27: Prostate Cancer, India, Sales Value ($m), 2001-2009
Table 28: Prostate Cancer, India, Annual Cost of Therapy ($), 2001-2009
Table 29: Prostate Cancer, India, Patient Volume (Thousands), 2001-2009
Table 30: Prostate Cancer, India, Treatment Usage Patterns, 2001-2009
Table 31: Prostate Cancer, India, Sales Value ($m), 2009-2020
Table 32: Prostate Cancer, India, Annual Cost of Therapy ($), 2009-2020
Table 33: Prostate Cancer, India, Patient Volume (Thousands), 2009-2020
Table 34: Prostate Cancer, India, Treatment Usage Patterns, 2009-2020
Table 35: Prostate Cancer, China, Sales Value ($m), 2001-2009
Table 36: Prostate Cancer, China, Annual Cost of Therapy ($), 2001-2009
Table 37: Prostate Cancer, China, Patient Volume (Thousands), 2001-2009
Table 38: Prostate Cancer, China, Treatment Usage Patterns, 2001-2009
Table 39: Prostate Cancer, China, Sales Value ($m), 2009-2020
Table 40: Prostate Cancer, China, Annual Cost of Therapy ($), 2009-2020
Table 41: Prostate Cancer, China, Patient Volume (Thousands), 2009-2020
Table 42: Prostate Cancer, China, Treatment Usage Patterns, 2009-2020
Table 43: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010
Table 44: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010
Table 45: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010
Table 46: Prostate Cancer, BRIC, Benchmarking Major Marketed Products, 2010
Table 47: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010
Table 48: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010
Table 49: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010
Table 50: Prostate Cancer, Global, Eligard, Regulatory Approval by Region
Table 51: Prostate Cancer, Global, Lupron, Efficacy End Point for Three Products
Table 52: Prostate Cancer, Global, Lupron, Incidence of Adverse Effects, 2010
Table 53: Prostate Cancer, Global, Licensing Agreements, 2009-2010
Table 54: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010
Table 55: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010
Table 56: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010
Table 57: Prostate Cancer, Global, Phase I Pipeline, August 2010
Table 58: Prostate Cancer, Global, Phase II Pipeline, August 2010
Table 59: Prostate Cancer, Global, Phase III Pipeline, August 2010
Table 60: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010
Table 61: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010
Table 62: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010
Table 63: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010
Table 64: Prostate Cancer, Global, M&A Deals by Geography, 2010
1.2 List of Figures
Figure 1: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2001-2020
Figure 2: Prostate Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action (%), 2010
Figure 3: Prostate Cancer Therapeutics Market, BRIC, Hormone-Independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010
Figure 4: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010
Figure 5: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2001–2009
Figure 6: Prostate Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2001–2009
Figure 7: Prostate Cancer Therapeutics Market, BRIC, Patient Volume, 2001–2009
Figure 8: Prostate Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2001–2009
Figure 9: Prostate Cancer Therapeutics Market, BRIC, Sales Value ($m), 2009–2020
Figure 10: Prostate Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2009–2020
Figure 11: Prostate Cancer Therapeutics Market, BRIC, Patient Volume (absolute), 2009–2020
Figure 12: Prostate Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2009–2020
Figure 13: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001-2009
Figure 14: Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001-2009
Figure 15: Prostate Cancer Therapeutics Market, Brazil, Patient Volume ('000s), 2001-2009
Figure 16: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2001-2009
Figure 17: Prostate Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2009
Figure 18: Prostate Cancer Therapeutics Market, Brazil, Historical Events Impact on the Market, 2010
Figure 19: Prostate Cancer Therapeutics Market, Brazil, Sales Value ($m), 2009-2020
Figure 20: Prostate Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2009-2020
Figure 21: Prostate Cancer Therapeutics Market, Brazil, Patient Volume ('000s), 2009-2020
Figure 22: Prostate Cancer Therapeutics Market, Brazil, Treatment Usage Patterns ('000s), 2009-2020
Figure 23: Prostate Cancer Therapeutics Market, Brazil, Future Events Expected to Impact the Market, 2010
Figure 24: Prostate Cancer, Russia, Sales Value ($m), 2001-2009
Figure 25: Prostate Cancer, Russia, Annual Cost of Therapy ($), 2001-2009
Figure 26: Prostate Cancer, Russia, Patient Volume (Thousands), 2001-2009
Figure 27: Prostate Cancer, Russia, Treatment Usage Patterns, 2001-2009
Figure 28: Prostate Cancer, Russia, Market Drivers and Restraints, 2009
Figure 29: Prostate Cancer, Russia, Historical Events Impact on the Market, 2010
Figure 30: Prostate Cancer, Russia , Sales Value ($m), 2009-2020
Figure 31: Prostate Cancer, Russia , Annual Cost of Therapy ($), 2009-2020
Figure 32: Prostate Cancer, Russia , Patient Volume (Thousands), 2009-2020
Figure 33: Prostate Cancer, Russia, Treatment Usage Patterns, 2009-2020
Figure 34: Prostate Cancer, Russia, Future Events Expected to Impact the Market, 2010
Figure 35: Prostate Cancer, India, Sales Value ($m), 2001-2009
Figure 36: Prostate Cancer, India, Annual Cost of Therapy ($), 2001-2009
Figure 37: Prostate Cancer, India, Patient Volume (Thousands), 2001-2009
Figure 38: Prostate Cancer, India, Treatment Usage Patterns, 2001-2009
Figure 39: Prostate Cancer, India, Market Drivers and Restraints, 2009
Figure 40: Prostate Cancer, India, Historical Events and Their Impact on the Market, 2010
Figure 41: Prostate Cancer, India, Sales Value ($m), 2009-2020
Figure 42: Prostate Cancer, India, Annual Cost of Therapy ($), 2009-2020
Figure 43: Prostate Cancer, India, Patient Volume (Thousands), 2009-2020
Figure 44: Prostate Cancer, India, Treatment Usage Patterns, 2009-2020
Figure 45: Prostate Cancer, India, Future Events Expected to Affect the Market, 2010
Figure 46: Prostate Cancer, China, Sales Value ($m), 2001-2009
Figure 47: Prostate Cancer, China, Annual Cost of Therapy ($), 2001-2009
Figure 48: Prostate Cancer, China, Patient Volume (Thousands), 2001-2009
Figure 49: Prostate Cancer, China, Treatment Usage Patterns, 2001-2009
Figure 50: Prostate Cancer, China, Market Drivers and Restraints, 2009
Figure 51: Prostate Cancer, China, Historical Events and Their Impact on the Market, 2010
Figure 52: Prostate Cancer, China, Sales Value ($m), 2009-2020
Figure 53 Prostate Cancer, China, Annual Cost of Therapy ($), 2009-2020
Figure 54: Prostate Cancer, China, Patient Volume (Thousands), 2009-2020
Figure 55: Prostate Cancer, China, Treatment Usage Patterns, 2009-2020
Figure 56: Prostate Cancer, China, Future Events Expected to Impact the Market, 2010
Figure 57: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010
Figure 58: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010
Figure 59: Prostate Cancer, Global, Taxotere, Chemical Structure
Figure 60: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010
Figure 61: Prostate Cancer, Global, Casodex, Chemical Structure
Figure 62: Prostate Cancer, Global, Casodex, LCM Activities, 2004-2010
Figure 63: Prostate Cancer, Global, Zoladex, Chemical Structure
Figure 64: Prostate Cancer, Global, Eligard , Chemical Structure
Figure 65: Prostate Cancer, Global, Lupron, Chemical Structure
Figure 66: Prostate Cancer, Global, Firmagon, Chemical Structure
Figure 67: Prostate Cancer, Global, Novatrone, Chemical Structure
Figure 68: Prostate Cancer, Global, Emcyt, Chemical Structure
Figure 69: Prostate Cancer, Global, Trelstar, Chemical Structure
Figure 70: Prostate Cancer, Global, Eulexin, Chemical Structure
Figure 71: Prostate Cancer, Global, Delestrogen, Chemical Structure
Figure 72: Prostate Cancer, Global, Gynodiol, Chemical Structure
Figure 73: Prostate Cancer, Global, Estrace, Chemical Structure
Figure 74: Prostate Cancer, Global, Tace, Chemical Structure
Figure 75: Prostate Cancer, Global, Nilandrone, Chemical Structure
Figure 76: Prostate Cancer, Global, Premarin, Chemical Structure
Figure 77: Prostate Cancer, Global, Clinical Trials by Therapy, 2010
Figure 78: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010
Figure 79: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010
Figure 80: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010
Figure 81: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010
Figure 82: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010
Figure 83: Prostate Cancer, Global, Licensing Agreements by Geography, 2010
Figure 84: Prostate Cancer, Global, Aflibercept, Chemical Structure
Figure 85: Prostate Cancer, Global, Abiraterone, Chemical Structure
Figure 86: Prostate Cancer, Global, Zibotentan, Chemical Structure
Figure 87: Prostate Cancer, Global, MDV3100, Chemical Structure
Figure 88: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010
Figure 89: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010
Figure 90: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010
Figure 91: Prostate Cancer, BRIC, Prostate Cancer, Opportunity and Unmet Need, 2010
Figure 92: Prostate Cancer, BRIC, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010
Figure 93: Prostate Cancer, BRIC, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010
Figure 94: Prostate Cancer, Global, Key Events Impacting the Future Market
Figure 95: Prostate Cancer, BRIC, Implications for Future Market Competition, 2010
Figure 96: Prostate Cancer, Global, Future Players in the Market, 2010
Figure 97: Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010
Figure 98: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010
Figure 99
To order this report:
Therapy Industry: Prostate Cancer - Brazil, China, India and Russia (BRIC) Drug Forecasts and Treatment Analysis to 2020
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT: |
|
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article